Flying The Web For News.
Featured Guest Posts
Dropshipping Guide
Shopify E-commerce Guide
Microsoft Exam Study
Business Opportunity Ideas
Microsoft Jobs News
Microsoft Exam
Writing Service Review
Slot Game Review
Data Recovery Review
Publicaciones Destacadas
Como ganar dinero por Internet
+ Larger Font | - Smaller Font
Share

Globe NewsWire News Distribution Service


DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, today announced clofazimine inhalation suspension (MNKD 101) will advance to an adaptive Phase 2/3 study. Additionally, a…


Posted: 2023-01-23 11:05:00

Get Full News Story On GlobeNewsWire Press Release Service



Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.



Related News Stories From The Web And More

Related Bing News Search Results

Press Release: MannKind’s Inhaled Clofazimine Will Advance to an Adaptive Phase 2/3 Study For Potential Treatment of Rare Lung Disease - Newscast

MannKind’s Inhaled Clofazimine Will Advance to an Adaptive Phase 2/3 Study For Potential ...

Mon, 23 Jan 2023 03:40:00 GMT Direct delivery of clofazimine to the lungs ... which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and ...

MannKind's Inhaled Clofazimine Will Advance to an Adaptive Phase 2/3 Study For Potential Treatment of Rare Lung Disease

Mon, 23 Jan 2023 03:29:00 GMT Jan. 23, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation MNKD, a company focused on the development and commercialization of inhaled therapeutic products ... health and the freedom to live life. This ...

MannKind’s Inhaled Clofazimine Will Advance to an Adaptive Phase 2/3 Study For Potential Treatment of Rare Lung Disease

Mon, 23 Jan 2023 03:18:00 GMT Get 7 Days Free Sign In Sign In Topics ...

MannKind's Inhaled Clofazimine Will Advance to an Adaptive Phase 2/3 Study For Potential Treatment of Rare Lung Disease

Mon, 23 Jan 2023 03:07:00 GMT Jan. 23, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products ... and the freedom to live life. This ...

MannKind's Inhaled Clofazimine Will Advance to an Adaptive Phase 2/3 Study For Potential Treatment of Rare Lung Disease

Sun, 22 Jan 2023 16:00:00 GMT "We are encouraged by the preclinical and Phase 1 data, and how inhaled ... press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind ...


Blow Us A Whistle